Back to Archived Journals » Gastrointestinal Cancer: Targets and Therapy » Volume 4

Emerging treatments for advanced pancreatic cancer: clinical potential of albumin-bound paclitaxel

Authors Fontana E, Sclafani F, Cunningham D

Received 15 January 2014

Accepted for publication 24 February 2014

Published 25 June 2014 Volume 2014:4 Pages 89—101


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 5

Elisa Fontana, Francesco Sclafani, David Cunningham

Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey, UK

Abstract: The management of pancreatic cancer has historically represented a major challenge for oncologists. The inherent aggressiveness of this tumor and the fibrotic features of the surrounding stromal tissue have significantly limited the impact of standard chemotherapy. Moreover, the paucity of available tumor tissue has hampered a better understanding of the biology of this disease as well as the development of new treatment strategies. Recently, the therapeutic landscape of metastatic pancreatic cancer has been enriched by two new combination regimens (FOLFIRINOX and gemcitabine-nab-paclitaxel) which have been demonstrated to improve the outcome in patients with good performance status. Moreover, the peritumoral stroma has been increasingly recognized as a potential therapeutic target for this disease, and several new agents targeting stromal components are currently under investigation. In this paper, we review the current treatment options for advanced pancreatic cancer, highlight the role of the peritumoral stroma, and discuss the clinical potential of nab-paclitaxel and antistromal treatment strategies.

Keywords: pancreatic cancer, nab-paclitaxel, stroma, SPARC

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]